The present invention relates to hydroxamic acid derivatives that are inhibitors of histone deacetylase (HDAC).
本发明涉及作为组蛋白脱乙酰基酶（HDAC）抑制剂的异羟肟酸衍 生物。
Histone deacetylase inhibitors increase the acetylation level of histone as well as some non-histone proteins, and specifically modulate some gene expression.
组蛋白去乙酰酶抑制剂可提高组蛋白的乙酰化水平，并对一些非组蛋白成分产生影响，从而调节某些特定基因的表达。
HDAC and histone deacetylase inhibitors (HDI) can affect expression of some specific genes and induce cell differentiation growth arrest and apoptosis through regulating histone acetylation level.
组蛋白脱乙酰基酶与组蛋白脱乙酰基酶抑制剂通过对组蛋白乙酰化水平的调控，影响特定基因的表达，改变细胞周期的进程。
In recognition of the need to develop novel therapeutic agents, the present invention provides novel histone deacetylase inhibitors.
认识到开发新颖治疗剂的要求，本发明提供新颖组蛋白去乙酰化酶抑制剂。
Histone deacetylase inhibitors decrease the antigen presenting activity of murine bone marrow derived dendritic cells.
组蛋白去乙酰酶抑制剂降低抗原提呈小鼠骨髓来源的树突状细胞的活性。
The pharmacological actions of histone deacetylase inhibitors and their potential clinical use…
综述了组蛋白去乙酰酶抑制剂的药理作用及其临床应用前景。
Purpose: Histone deacetylase inhibitors (HDACi) are being studied in clinical trials with the aim to induce cellular differentiation, growth arrest, and apoptosis of tumor cells.
目的：临床试验中对组蛋白脱乙酰基酶阻滞剂(HDACi)的研究目的在于诱导细胞分化，生长停止，和肿瘤细胞的凋亡。
The pharmacological actions of histone deacetylase inhibitors and their potential clinic…
综述了组蛋白去乙酰酶抑制剂的药理作用及其临床应用前景。
The pharmacological actions of histone deacetylase inhibitors and their potential clinic…
综述了组蛋白去乙酰酶抑制剂的药理作用及其临床应用前景。
应用推荐